ESMO
<ѻý class="page-description">European Society for Medical Oncologyѻý>Cancer patients with cachexia added needed pounds with GDF-15 antibody
"Nodal radiotherapy for breast cancer no longer needs 5 weeks," researcher says
Absolute difference of 4.9% at 5 years, including a benefit for patients who did not achieve pCR
Potential new option for patients with previously treated extrapancreatic or pancreatic NETs
Results "practice-changing," says expert
Adding lenvatinib, pembrolizumab to TACE significantly improved PFS, numerically improved OS
Hazards for radiographic PFS, OS reduced by 31% with enzalutamide plus Ra-223
POD1UM-303/InterAACT 2 data also trend in the direction of better overall survival
But combination may be appropriate for shrinking tumors before surgery
Second-line T-DXd best option in patients with and without intracranial activity, experts says
Data support that ICI rechallenge should be discouraged in patients with advanced RCC
Follow-up results from phase II study show 12-month EFS rate of 89% in stage II-IV disease
Time to radiographic progression doubled with 177Lu-PSMA-617
Amivantamab-based regimens improved oncologic outcomes, but with more side effects
-
ASTRO: American Society for Radiation Oncology
September 2024
-
ESMO: European Society for Medical Oncology
September 2024
-
ASCO: American Society of Clinical Oncology
May 2024
-
AACR: American Association for Cancer Research
April 2024